- The document is a transcript of the earnings conference call held on July 29, 2026, to discuss the Un-audited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 (Q1 FY27).
- The event was an earnings call / post-results investor interaction. The date of the event was July 29, 2026; a specific time was not mentioned in the provided transcript.
- The stated purpose of the event was to discuss the company's Q1 FY27 financial and operational performance and provide a strategic update, particularly on its oncology business.
- The meeting was held after the earnings announcement, as it is a discussion of the results for the quarter ended June 30, 2026.
- Management participants on the call included:
- Mr. Bikramjit Ghosh – Vice President, Strategy and Business Development
- Mr. Dharmesh Thaker – Chief Financial Officer
- Mr. Bharat Soni – Company Secretary
- Ms. Pushpa Ponmany – Manager
- The moderator for the call was Ms. Sejal from MUFG Intime.
- The transcript itself was made available on the company's website at https://www.sakarhealthcare.com/pdf/Sakar-Q1-FY27-Earnings-Conference-Call-Transcript.pdf and filed with the exchange.
- The call began with a standard disclaimer that it may contain forward-looking statements based on the company's business opinions and expectations as of the date of the call.
Financial Highlights Disclosed in the Transcript:
The management provided a detailed financial and operational summary during the call:
- Revenue from operations for Q1 FY27 stood at INR 7,297 lakhs (INR 72.97 Cr), delivering a year-on-year growth of 38%.
- EBITDA increased by 67% to INR 2,125 lakhs (INR 21.25 Cr).
- EBITDA margins improved to 29%.
- Profit after tax (PAT) stood at INR 1,028 lakhs (INR 10.28 Cr), recording a growth of 120% over the corresponding quarter of the previous year.
- The oncology division revenue for the quarter was INR 33 Cr, of which INR 6.5 Cr was from exports and the rest was domestic.
Forward-Looking Statements & Strategic Themes:
- Strategy: The company aims to evolve into a predominantly oncology-led export franchise.
- Facility Potential: The integrated EU-GMP approved oncology facility at Bavla is seen as capable of supporting revenues of INR 800 Cr to INR 1,000 Cr at optimal utilization over the next 4 to 5 years without requiring major incremental capital expenditure.
- Oncology Business Guidance: Management guided for doubling oncology revenue in FY27 (from ~INR 95 Cr in FY26 to ~INR 200 Cr) and expects it to reach ~INR 280-300 Cr in FY28.
- Export Growth: Export contribution within oncology is expected to grow significantly, from INR 6.5 Cr in Q1 FY27 to ~INR 60-70 Cr for full-year FY27 and potentially double again in FY28.
- Margin Outlook: EBITDA margins are expected to improve further, potentially crossing 30% by the end of FY27 and reaching around 35%+ for products with backward-integrated APIs.
- Operational Metrics:
- Executed over 65 oncology product contracts in the quarter.
- 178 oncology dossiers submitted globally; 16 marketing authorizations received.
- 26 European filings completed, including 15 own filings.
- 55 oncology molecules developed; 32 dossiers ready for launch.
- 33 ongoing oncology technology transfer projects with companies like Accord-Intas, Torrent, Emcure, Glenmark, and Zydus.
- 7 technology transfer projects have received site variation approvals in the UK/EU.
- 21 oncology APIs developed in-house; 2 have CEP approvals (Gefitinib, Cytarabine); 5 more CEP applications are ongoing.
Additional Notes Section
- The document is an enclosure to a regulatory filing (Disclosure under Regulation 30 of SEBI LODR Regulations, 2015) and contains the full transcript of the earnings conference call.
- The transcript contains extensive financial data, operational metrics, and forward-looking guidance as presented by management during the call.
- The filing was signed by Bharatkumar Sukhlal Soni, Company Secretary and Compliance Officer, on August 3, 2026.